Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
BS BSX BOSTON SCIENTIFIC CORP FY ended Jan 30, 2026 | $49.01 | $71.03B | $82.27B | $20.07B | $5.10B | $2.89B | 25.26x | 3.54x | 15.18x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $92.04 | $117.82B | $134.91B | $36.36B | $9.78B | $4.80B | 24.68x | 3.24x | 12.79x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $111.04 | $193.41B | $207.36B | $44.33B | $12.22B | $6.52B | 29.85x | 4.36x | 16.25x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $280.80 | $676.70B | $734.11B | $94.19B | $37.95B | $26.80B | 25.46x | 7.18x | 18.44x |
LI LIVN LivaNova PLC FY ended Feb 18, 2026 | $80.16 | $4.42B | $4.59B | $1.39B | -$115.72M | -$242.47M | -18.01x | 3.18x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 14.79x | 4/5 | $1.19B | $41.24 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.30x | 5/5 | $3.92B | $135.69 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 17.45x | 5/5 | $2.54B | $87.76 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
BS BSX BOSTON SCIENTIFIC CORP FY ended Jan 30, 2026 | $49.01 | $71.03B | $82.27B | $20.07B | $5.10B | $2.89B | 25.26x | 3.54x | 15.18x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $92.04 | $117.82B | $134.91B | $36.36B | $9.78B | $4.80B | 24.68x | 3.24x | 12.79x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $111.04 | $193.41B | $207.36B | $44.33B | $12.22B | $6.52B | 29.85x | 4.36x | 16.25x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $280.80 | $676.70B | $734.11B | $94.19B | $37.95B | $26.80B | 25.46x | 7.18x | 18.44x |
LI LIVN LivaNova PLC FY ended Feb 18, 2026 | $80.16 | $4.42B | $4.59B | $1.39B | -$115.72M | -$242.47M | -18.01x | 3.18x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 14.79x | 4/5 | $1.19B | $41.24 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.30x | 5/5 | $3.92B | $135.69 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 17.45x | 5/5 | $2.54B | $87.76 | Included in the active peer mix. |
